Ran Nussbaum
CIK 1609805 · last filed 2026-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$109.80M
Companies
6
Total Filings
53
Lifetime Open-Market Net
$25.28M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LBRX | Director | 1,411,681 | $34.94 | $49.32M | $15.00M | 3 | 2026-06-05 |
| KROS | Director | 160,512 | $10.07 | $1.62M | $25.00M | 9 | 2025-06-11 |
| URGN | Director | 1,437,169 | $40.88 | $58.75M | $0 | 11 | 2023-02-28 |
| ELOX | Director | 8,363 | $12.81 | $107.1K | $13.21M | 9 | 2022-06-17 |
| Prevail Therapeutics Inc. (PRVL) Delisted | Director | — | — | — | $0 | 1 | 2020-06-19 |
| Kite Pharma, Inc. (KITE) Delisted | Director | 7,880 | — | — | -$27.94M | 6 | 2017-06-22 |
Recent Filings · Page 4 of 6
53 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-09-16 | — | Exer (X) | +114,286 | $200.0K | |
| 2019-07-01 | — | Buy (P) | +307,692 | $3.00M | |
| 2019-06-26 | ELOX | Buy (P) | +200,000 | $1.80M | EDGAR |
| 2019-06-05 | URGN | Grant (A) | — | $0 | EDGAR |
| 2019-05-30 | ELOX | Grant (A) | — | $0 | EDGAR |
| 2019-05-29 | ELOX | Grant (A) | — | $0 | EDGAR |
| 2019-05-15 | — | Grant (A) | — | $0 | |
| 2018-10-22 | — | Buy (P) | +181,818 | $1000.0K | |
| 2018-06-19 | ELOX | Grant (A) | — | $0 | EDGAR |
| 2018-05-25 | — | Other (J) | +6,608,000 | $0 |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.